Notizie AIOM – anno XV n. 635

27 Giugno 2017

The impact of baseline Edmonton Symptom Assessment Scale scores on treatment and survival in patients with advanced non-small cell lung cancer

Palliative systemic therapy is frequently underutilsed in patients with advanced non-small cell lung cancer, for many reasons. The aim of this study was to identify patient-reported factors that may predict for treatment decisions and survival in advanced NSCLC, using the ...
Leggi tutto

27 Giugno 2017

Randomized, Noncomparative, Phase II Trial of Early Switch from Docetaxel to Cabazitaxel or Vice Versa,With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer

The TAXYNERGY trial clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. Patients were ...
Leggi tutto

27 Giugno 2017

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) -positive advanced solid tumors. The results from ...
Leggi tutto

26 Giugno 2017

ASTRO Issues Guideline for Use of Stereotactic Radiation in Early-Stage Lung Cancer

June 15, 2017 - The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer. While SBRT is the current standard of care for peripherally located tumors in patients ...
Leggi tutto

26 Giugno 2017

ASCO Says Senate Healthcare Bill Is a Disappointment

June 22, 2017 - Senate Republicans have introduced a healthcare bill that would revise many of the changes imposed by the Patient Protection and Affordable Care Act (ACA), cutting federal support for Medicaid and repealing the individual and employer mandates for having ...
Leggi tutto

26 Giugno 2017

NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer

June 23, 2017 - According to Surveillance, Epidemiology, and End Results (SEER) data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the National ...
Leggi tutto

26 Giugno 2017

Copanlisib Lymphoma Data Updated as FDA Considers Approval

June 17, 2017 - Copanlisib showed an objective response rate (ORR) of 59.2% (95% CI, 50.6%-67.3%) without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma, according to findings from the ...
Leggi tutto

26 Giugno 2017

FDA Accepts Denosumab sBLA for Multiple Myeloma

June 19, 2017 - The FDA has accepted a supplemental biologics license application (sBLA) for the use of denosumab for the prevention of skeletal-related events (SREs) in patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor. The sBLA ...
Leggi tutto

26 Giugno 2017

FDA Approves Aminolevulinic Acid Hydrochloride as an Optical Imaging Agent Indicated in Gliomas

June 20, 2017 - On June 6, the U.S. Food and Drug Administration (FDA) approved aminolevulinic acid hydrochloride, known as ALA HCl, as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV) for preoperative imaging, ...
Leggi tutto

26 Giugno 2017

FDA Approval Sought for Brentuximab Vedotin in CTCL

June 21, 2017 - A supplemental Biologics License Application (sBLA) has been submitted to the FDA for brentuximab vedotin as a treatment for patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate with Takeda. ...
Leggi tutto

LAVORIAMO CON

News

MEDICINA DI LABORATORIO, OLTRE IL 70% DELLE DECISIONI CLINICHE DIPENDE DALLE ANALISI. PRESENTATO IL PRIMO STUDIO NAZIONALE SULL’APPLICAZIONE DEL NUOVO NOMENCLATORE TARIFFARIO

TUMORI: “CNAO È CENTRO DI RIFERIMENTO MONDIALE NELL’ADROTERAPIA. A OGGI TRATTATI PIÙ DI 6.200 PAZIENTI”

MALATTIE AUTOIMMUNI: AL GIFFONI FILM FESTIVAL ARRIVA “PIÙ FORTE IO”. CON TENACIA E NUOVE TERAPIE POSSIBILE SUPERARE LE PATOLOGIE CRONICHE

L’OCULISTA: ANCHE IN ESTATE POSSIBILE FARSI OPERARE DI GLAUCOMA. PER PROTEGGERE GLI OCCHI BASTANO MASCHERINE, CAPPELLINI E OCCHIALI

MEDICINA DI LABORATORIO, I CLINICI ITALIANI RICONOSCIUTI TRA LE ECCELLENZE INTERNAZIONALI. “IL NOSTRO PAESE TRA I PROTAGONISTI DELL’EVOLUZIONE DELLA DIAGNOSTICA NEL MONDO”

TUMORE DELL’OVAIO, 1 DONNA SU 3 ASPETTA PIÙ DI UN ANNO PER LA DIAGNOSI. “NECESSARIO AUMENTARE L’ACCESSO AI CENTRI AD ALTO VOLUME, AL SUPPORTO PSICONCOLOGICO E ALL’INNOVAZIONE TERAPEUTICA”

TUMORE DEL SENO, IN ITALIA 950MILA DONNE VIVONO CON UNA DIAGNOSI. ROPI: ‘RACCOMANDATI ALMENO 150 MINUTI D’ATTIVITA’ FISICA ALLA SETTIMANA’

Notizie AIOM – anno XV n. 635

The impact of baseline Edmonton Symptom Assessment Scale scores on treatment and survival in patients with advanced non-small cell lung cancer

Randomized, Noncomparative, Phase II Trial of Early Switch from Docetaxel to Cabazitaxel or Vice Versa,With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

ASTRO Issues Guideline for Use of Stereotactic Radiation in Early-Stage Lung Cancer

ASCO Says Senate Healthcare Bill Is a Disappointment

NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer

Copanlisib Lymphoma Data Updated as FDA Considers Approval

FDA Accepts Denosumab sBLA for Multiple Myeloma

FDA Approves Aminolevulinic Acid Hydrochloride as an Optical Imaging Agent Indicated in Gliomas

FDA Approval Sought for Brentuximab Vedotin in CTCL